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Recent estimations provided by GloboCa 2008 \[[@B1]\] indicate that in 2008 12.7 million new cancer cases and 7.6 million cancer deaths occurred in the world and that most of these cancers are present in developing countries either in terms of incidence (56%) or mortality (63%). It is also expected that by 2030 some 21.4 million new cancer cases will be diagnosed and over 13.2 million cancer deaths will occur annually. It is estimated that liver cancer (mostly hepatocellular carcinoma \[HCC\]) is responsible for more that 600,000 cancer deaths worldwide and represents the third most frequent cause of cancer deaths \[[@B2],[@B3]\]. The major causes of hepatocellular carcinoma have been known since several decades and in the developing countries these are HBV, HCV infections and exposure to aflatoxins through the diet \[[@B4]-[@B6]\]. Since the early 1980s an efficient and safe vaccine against HBV infection has been available and various intervention studies, namely in Quidong Province, China \[[@B7]\], Taiwan \[[@B8]\], and The Gambia \[[@B9]\], have been initiated to assess the efficacy of HBV vaccination at infancy in the prevention of HCC.

All the children vaccinated within the Gambia Hepatitis Intervention Study (GHIS) were registered, resulting in two cohorts of approximately 60,000 children, one of which received only the routine EPI vaccination and the other the HBV vaccine in addition. To determine the response to HBV vaccine and the persistence of vaccine-induced immunity, some 1000 children were recruited consecutively and these have been followed annually to assess their HBV serological status. A cross-sectional survey was carried out at the ages of 4 and 9 years of a similar number of unvaccinated children to determine the vaccine efficacy against HBV carriage status and infection.

The vaccine efficacy shows an 84% protection against infection and 94% against HBV chronic carriage at 9 years of age (See Table [1](#T1){ref-type="table"}). The evaluation of the expected protection against the development of HCC is expected from the year 2017 \[[@B10]\]. Similar intervention studies have been carried out in South-East Asia see \[[@B7],[@B11]\]. It is of interest to note that, in the Chinese population, perinatal transmission from mothers positive for HBVe antigen is frequent, whereas in Africa horizontal transmission (sibling-to-sibling) is prevalent. The study in Taiwan shows that the incidence rate of HCC in children of 6-19 years of age was considerably lower in children born after the initiation of the HBV vaccination and that this decrease was not present in children born from mothers who were positive for HBsAg and HBeAg \[[@B11]\]. These studies in Africa and South-East Asia indicate that the natural history of HBV infection differs in these populations and they have a direct relevance in the implementation of HBVvaccination strategy.

###### 

Hepatitis B vaccination trials

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Location\           Year of recruitment/ year of Follow up   Prevalence HBsAg\                       Efficacy   Relative Risk of developing HCC\
  No. of subjects                                              Non-vaccinated/ vaccinated population              Non-vaccinated/ vaccinated population
  ------------------- ---------------------------------------- --------------------------------------- ---------- ---------------------------------------
  **The Gambia**\*\   1986-1990/ 9 yrs                         10% \> 1%                               94%        Expected 2017
  \>60000                                                                                                         

  **China**\*\        1984-1990/ 11 yrs                        7,1% \> 1.66%                           75%        Expected \>2015
  (Qidong)\>38000                                                                                                 

  **Taiwan**^♦^       1984                                     9.8% in 1984 \> 0.7% in 1999            84%        0.31^■^
  -------------------------------------------------------------------------------------------------------------------------------------------------------

\*HBV vaccination trials programme \[[@B16],[@B7]\]

^♦^Universal vaccination programme \[[@B11]\]

^■^64 HCC among vaccinees in 37709304 person-years versus 444 HCC in unvaccinated subjects in 78496406 person-years \[[@B11]\]

It has been estimated that, in a surviving birth cohort for the year 2000, routine infant HBV vaccination, with a 90% coverage and the first dose administered at birth, would prevent 84% of global HBV related deaths, i.e. 1.4 million \[[@B12]\].

In The Gambia the high incidence of HCC is also associated with exposure to the carcinogen aflatoxin B~1~ through the consumption of groundnuts and maize contaminated with the fungi *Aspergillus flavus* and *parasiticum*\[[@B6]\]. Comprehensive studies have been carried out in this country to assess the relative contribution and the interaction of the different risk factors, namely HBV infection and aflatoxin B~1~, in the etiopathogenesis of HCC \[[@B13],[@B14]\]. These case-control studies, using serological markers of exposure to HBV and aflatoxin B~1~ (as determined by the presence of aflatoxin-albumin adduct and of 249^ser^ p53 mutation in sera DNA), clearly show that exposure to aflatoxins affects the entire population and that exposure to both HBV infection and aflatoxins results in a prominent increase risk of developing HCC.

In summary, these studies show that HBV vaccination programmes have been successfully implemented in various parts of the world. In addition, molecular epidemiological studies in The Gambia and in South-East Asia have clearly shown the relevance of other major risk factors, namely aflatoxin exposure \[[@B15]\], in the etiopathogenesis of HCC.
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